search

BioNTech chief: No need yet to adapt Pfizer vaccine for COVID variants

A vial of Pfizer-Biontech COVID-19 vaccine is seen at a Clalit health clinic in Jerusalem on August 8, 2021. (Olivier Fitoussi/Flash90)
A vial of Pfizer-Biontech COVID-19 vaccine is seen at a Clalit health clinic in Jerusalem on August 8, 2021. (Olivier Fitoussi/Flash90)

BERLIN — The first generation vaccine developed by BioNTech-Pfizer works against coronavirus variants such as the Delta strain and does not need to be modified for the moment, the chief executive of German company BioNTech says.

“It is quite possible that in the next six to 12 months, further variants will emerge and that would require adaptation of the vaccine but it is at the moment not yet the case,” Ugur Sahin tells journalists.

comments
Never miss breaking news on Israel
Get notifications to stay updated
You're subscribed